Top Tech Companies (2,068)
Don't see your company?
Create a company profile
Headquartered in San Diego, CA, iXCells Biotechnologies is a leading cell biology and cell technology company specializing in preclinical drug discovery solutions with focus on disease relevant cellular models enabling technologies and services to the academic, biotech and pharma communities. iXCells provides high quality primary cells normal and diseased iPS cell lines, iPSC-derived cell products, custom iPSC services, functional bioassay development and execution, among other products and services.
Andelyn Biosciences is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into Reality™. Capabilities span viral vector and vaccine process and analytical development, small to large scale adherent and suspension based GMP drug substance manufacturing up to 2000L, and finished drug product manufacturing services located in Columbus, OH USA. Having 20+ years of experience with viral vector and vaccine manufacturing, Andelyn offers its clients direct access to globally recognized thought leaders with troubleshooting / characterization expertise and GMP material produced for over 75+ worldwide clinical trials. In addition to producing over 400+ cGMP clinical batches and 2000+ research-grade productions, Andelyn currently provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing (early 2022), advanced quality systems, full regulatory support, semi-automated to automated fill stations, and supply chain vertical integration. Its state-of-the-art 185,000 sq ft clinical and commercial manufacturing facility comprises 14+ upstream production suites for customization of new programs and tech transferred programs. Andelyn offers clinical through commercial-scale capabilities that will help accelerate the development and manufacturing of innovative therapies to bring more treatments to more patients
BHI is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. It is a private-public partnership in the form of a 501 (c)(3) nonprofit that connects the Region’s innovation assets to provide integrated technical knowledge, financial means and entrepreneurial/managerial expertise to turn promise into prosperity for the region while advancing human health. BHI will accomplish its mission by building an entrepreneurial ecosystem, working directly with federal and academic technology transfer offices, making various types of risk capital readily available to promising biohealth startups, strengthening and connecting the local supply of industry talent, developing a regional brand and reputation, and advocating for improved business and regulatory conditions in the industry.
PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges.
Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases. The Company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA, and Munich, Germany.
Dompé is an Italian bio-pharmaceutical company that focuses on innovation, where a long tradition in the field of personal wellness goes hand in hand with a commitment to research and development to meet hitherto unsatisfied therapeutic needs. Established in 1940 in Milan, Dompé continues to have its headquarters in this city. In Italy, it also has offices in L’Aquila, with an industrial and biotech research hub, and in Naples, where the Company has an R&D division. Dompé also has branches in the United States (Boston and San Francisco), in Albania (Tirana) and China (Shanghai). Primary Care Dompé, with its products offered at over 10,000 pharmacies in Italy, is engaged in the development and distribution of ethical drugs and self-medication, adjuvants, medical devices and cosmetics, and in the fields of vitamin and mineral supplements and personal hygiene. The therapeutic areas include cardiovascular, gastrointestinal, paediatrics, neurology, urology, ophthalmic, stomatology and respiratory. Dompé currently markets 50 million medication packages in roughly 40 countries around the world. Biotech and rare diseases The Biotech unit is a manifestation of Dompé commitment to meeting unsatisfied patient needs all around the world. The Biotech Unit focuses specifically on the rare diseases field, such as ophthalmology, for instance, an area in which the company has developed and marketed the first ophthalmic product based on rhNGF (the molecule discovered by Nobel Prize winner Rita Levi Montalcini) for patients suffering from neurotrophic keratitis. For more information on Dompé visit www.dompe.com To explore career opportunities at Dompé visit http://www.dompe.com/Careers-en/
Aqua-Chem is the leader in providing Global Water Solutions. We develop innovative and comprehensive water solutions for Beverage, Pharmaceutical, Commercial Marine, MIlitary, and Industrial markets. We pride ourselves on the fact that Aqua-Chem is the premier water treatment company in the world. Water Solutions begin and end with Aqua-Chem. For information on career opportunities with Aqua-Chem, please copy and paste this link in your browser: http://aquachem.iapplicants.com
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address. For more information, please visit the Senti Bio website at https://www.sentibio.com.
Carmot Therapeutics, Inc. is a clinical-stage company dedicated to the discovery and development of innovative medicines. Carmot applies a transformative, patented drug discovery approach, Chemotype Evolution to explore novel frontiers of chemistry and biology. Using Chemotype Evolution, Carmot has developed a portfolio of drug candidates in metabolic disease and oncology.
Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families. Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development. Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on people’s lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.
About Enzyvant Enzyvant is a biopharmaceutical company making life-altering impact for people affected by rare disease, where communities are small, and the human need is immense. Enzyvant partners with these communities to accelerate development of transformative medicines, collaborating with academia, industry, physician associations, advocacy groups and government, because strong relationships make bold science possible. Enzyvant has capabilities spanning non-clinical and clinical development and commercialization and is developing in-house manufacturing. The company delivered one of the first Regenerative Medicine Advanced Therapy products and makes promising advances against some of the greatest challenges in immunology and cardiopulmonology. For more information about Enzyvant, visit www.Enzyvant.com.
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Our pipeline includes two investigational oral SYK inhibitors, entospletinib and lanraplenib, which are being developed to treat acute myeloid leukemia (AML). Together the compounds have the potential to target mutations present in more than two-thirds of patients with AML. We are also advancing an oral CDK9 inhibitor, KB-0742, to treat patients with solid tumors addicted to oncogenic transcription factor activity. KB-0742 is the first investigational medicine from our internal discovery platform to enter the clinic. Beyond these three investigational compounds, we are progressing additional discovery programs, including one focused on the MYC TRN and another focused on the AR TRN. For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW.
Life Edit is a next-generation gene editing company dedicated to paving the way to faster, safer, more innovative gene editing therapeutics that treat diseases once thought to be incurable. Our platform allows us to target any genomic sequence and develop life-changing therapies for the most challenging genetic disorders. Life Edit has one of the world’s largest and most diverse arrays of novel RNA-guided nucleases and base editors that are active in mammalian cells. They were developed from a proprietary collection of non-pathogenic organisms, and offer gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. Our genome editing platform is derived from AgBiome’s proprietary collection of tens of thousands of microbes. We retain access to this growing microbial collection to mine for gene editing systems with uses in human therapeutics. Life Edit is an Elevatebio portfolio company. We are focused on strengthening our platform, developing a pipeline of gene therapies, and sharing our expertise through strategic partnerships.
Our mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction by leveraging a deep mechanistic understanding of mitochondrial biology. Mitochondria are essential energy-converting cellular organelles found in nearly every cell type throughout the body. Dysfunctional mitochondria are involved in more than 50 diseases. The most severe of these are broadly termed mitochondrial diseases, a group of rare genetic conditions which affect individuals of all ages. Mitochondrial dysfunction also plays an important role in more common diseases, including aging-related disorders. At Pretzel, we are developing first-in-class therapeutics that can address mitochondrial dysfunction at its roots. By taking aim at the genetic drivers of mitochondrial dysfunction, we believe our approach could be effective across a wide range of diseases which lack meaningful treatment options today.
Aerami Therapeutics is developing a new generation of inhaled therapies for the treatment of severe respiratory and chronic diseases. Our platform is designed to overcome the limitations of injectable, oral, and other inhaled formulation technologies for managing severe respiratory and chronic diseases. Ultimately, our aim is to improve treatment efficacy and improve patient lives. To learn more, visit: https://aerami.com/
A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.
Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.
Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.
RS BioTherapeutic’s first investigational compound (RSBT-001) is a semi-synthetic, nebulized, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. Our premise is that RSBT1 provides therapeutic benefit through modulation of the Interleukin response to inflammation and modulation of alveolar macrophages responsible for fibrotic changes within the lungs. RSBT-001 is unique in that it is a polar adaptive molecule exhibiting both hydrophilic and lipophilic properties, which leads to high absorption and bioavailability enhancing therapeutic benefit.
DermBiont’s mission is to become the world’s leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent diseases. The company aims to impact the root causes of skin diseases through the development of targeted small molecule therapeutics with well-defined mechanisms of action and biotherapeutics that repair an imbalance of the microbiome. The company’s targeted topical therapeutics pipeline includes SM-020 for the treatment of seborrheic keratosis, SM-030 for the treatment of hyperpigmentation disorders of the skin, and DBI-001 & DBI-002 for the treatment of atopic dermatitis, tinea pedis, and onychomycosis. For more information, please visit www.dermbiont.com.
